-
The development of the API market continues to improve, what is the impact on pharmaceutical enterprises?
Time of Update: 2023-01-01
epilogue epilogue In general, in the context of the broad prospects of the API industry, API equipment companies will undoubtedly usher in new development opportunities.
In general, in the context of the broad prospects of the API industry, API equipment companies will undoubtedly usher in new development opportunities.
-
In the past month, many pharmaceutical companies announced that they had passed the GMP compliance inspection of drugs
Time of Update: 2023-01-01
The company said that the on-site compliance inspection of drug GMP this time shows that the relevant dosage form production line of Junyuan Pharmaceutical meets the GMP requirements.
-
Targeted drugs are too expensive to use? The industry calls for more targeted drugs to enter medical insurance
Time of Update: 2023-01-01
The industry calls for more targeted drugs into medical insurance (Image source: Pharmaceutical Network) In recent years, with the flow of targeted drugs and immune drugs into the market, patients have brought new means and new hopes for treatment, but the price of targeted drugs is often expensive, and many patients' families face the burden of expensive drug costs, and can only look forward to drugs.
-
The State Food and Drug Administration held a special rectification work conference on rural drug safety
Time of Update: 2023-01-01
Xu Jinghe stressed that drug regulatory departments at all levels should conscientiously implement the decision-making and deployment of the Party Central Committee and the State Council, and in accordance with the overall requirements of the special rectification action, work hard and for a long time, and persistently do a good job in rural drug safety supervision and special rectification work.
-
The State Food and Drug Administration and the Hainan Provincial Government have further promoted the pilot work of real-world data application in the clinical trial of drugs and devices
Time of Update: 2023-01-01
On December 7, 2022, the State Food and Drug Administration and the Hainan Provincial Government jointly held the fourth meeting of the 2022 Leading Group for the Pilot Work of Clinical Real-World Da
-
Biopharmaceutical companies are accelerating asset integration and returning to the "essence"
Time of Update: 2023-01-01
js?cdnversion='+~(-new Date()/36e5)];Since the beginning of this year, a large number of biotechnology companies are actively adjusting asset projects and R&D pipelines to promote the company's cost reduction and efficiency increase, as well as return to the "essence".
-
In November, a number of new drugs in China were approved, involving anti-influenza, breast cancer...
Time of Update: 2023-01-01
The drug was submitted for clinical application on November 21, 2003, and the marketing application was accepted by CDE in 2018, and finally approved for marketing after nearly 5 years of review On November 9, according to the website of the National Medical Products Administration, linperlisib, trade name: Intarui) was conditionally approved by the State Food and Drug Administration for adult patients with relapsed or refractory follicular lymphoma who have received at least two previous systemic treatments.
-
In November, a large number of pharmaceutical companies were fined, involving the production of inferior drugs and failing to correct problems...
Time of Update: 2023-01-01
Since the implementation of the new version of the Drug Administration Law, industry supervision has become stricter, and relevant departments have repeatedly struck hard to strictly investigate whether the production and operation behavior of pharmaceutical companies complies with the regulations, and in this context, many pharmaceutical companies have been fined for the production and sale of counterfeit drugs, environmental protection, and failure to correct problems.
-
Domestic new drug research and development is in full swing, and this issue is gradually becoming the focus of pharmaceutical companies
Time of Update: 2023-01-01
Domestic new drug research and development is hot, this problem has become the focus of pharmaceutical companies (Image source: Pharmaceutical Network) On November 16, Hengrui Pharmaceutical also announced that 3 drugs have obtained clinical trial approval notices and will carry out clinical trials in the near future.
-
The amount of new traditional Chinese medicine drugs is imminent, and the industry is optimistic about the traditional Chinese medicine enterprises that gnaw the "hard bones" under the research
Time of Update: 2023-01-01
js?cdnversion='+~(-new Date()/36e5)];In recent years, with the acceleration of the review and approval of innovative Chinese medicine drugs and the implementation of a number of substantial favorable policies for traditional Chinese medicine, China's innovative drug industry has developed rapidly, and the approval of new drugs has been increasing, since 2017, a total of 19 innovative traditional Chinese medicine drugs have been approved, of which 8 products have been approved for marketing in 2021, a record number.
-
The senior management of local pharmaceutical companies is still changing frequently, and some veterans also choose to "leave"
Time of Update: 2023-01-01
js?cdnversion='+~(-new Date()/36e5)];On November 30, Shapuai Pharmaceutical issued an announcement that Mr. Hu Zhengguo, a director of the company, applied to resign as a director of the company's fifth board of directors due to personal reasons.
-
Note that these acts of producing medical devices will be punished! Some companies were fined millions of dollars
Time of Update: 2023-01-01
Recently, a news disclosed on the website of the Shenzhen Market Supervision Bureau that a company was fined more than 160,000 yuan for producing Class II medical devices that did not meet the technical requirements of the product attracted attention and heated discussions in the industry.
-
With the continuous promotion of centralized procurement, the competition in the tens of billions of stapler market is constantly intensifying
Time of Update: 2023-01-01
Therefore, at present, in the face of centralized procurement price reduction and fierce market competition, domestic head stapler companies are increasing research and development, laying out a new generation of stapler products, upgrading processes, improving production levels, and moving towards the high-end market.
-
Under the "involvement" of the domestic generic drug market, the "going abroad" of pharmaceutical companies is accelerating
Time of Update: 2023-01-01
It is worth mentioning that this year, Hengrui Pharmaceutical's contrast agent generic drug ANDA has obviously bloout, and the company's gadoterate glucosamine injection and iodixanol injection ANDA have also been approved by the FDA in April-May. Among them, iodixanol injection has also become the first generic drug in the US market, enjoying a 180-day market exclusivity period; According to the data, the global sales of iodixanol injection-related dosage forms are about 873 million US dollars.
-
HER2 exon 20 inserted mutation lung cancer (NSCLC) innovative drug! Pan-HER tyrosine kinase inhibitor poziotinib has suffered a major regulatory setback, and Luye Pharmaceutical has the rights in China!
Time of Update: 2023-01-01
The NDA seeks approval for poziotinib: a novel, oral, irreversible EGFR family receptor-blocking pan-HER inhibitor for the treatment of previously treated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying HER2 exon 20 insertion mutations (Ex20ins).
-
In this major pharmaceutical province, medical insurance will begin to pay back directly to pharmaceutical companies!
Time of Update: 2023-01-01
For example, recently, the Hainan Provincial Medical Insurance Bureau issued the Notice on the Implementation Plan for Drug Listing Procurement in Hainan Province (hereinafter referred to as the "Notice"), Article 12 of which mentions that it is necessary to explore the settlement of drug payments through direct payment by medical insurance funds, establish a drug settlement mechanism suitable for the construction of Hainan Free Trade Port, and gradually solve the problem of difficulty in collecting payments by pharmaceutical enterprises.
-
100 proprietary Chinese medicines are amazing! 3.8 billion "miracle medicine" leads, exclusive varieties dominate the screen
Time of Update: 2023-01-01
7 more than 1 billion proprietary Chinese medicines are eye-catching From the sales point of view, the total sales scale of 100 proprietary Chinese medicines in the terminal of China's urban physical pharmacies in 2022E will exceed 35 billion yuan, of which 7 proprietary Chinese medicines will exceed 1 billion yuan, including Angong Niuhuang Pill, Huo Xiang Zhengqi Oral Liquid, Stomach Elimination Tablets, Kyoto Nianci Honey Refining Chuanbei Loquat Ointment, Lianhua Qingwen Capsules, Pian Zixi (lozenges) and Enteritis Ning tablets.
-
At the end of the year, the "acquisition wave" of domestic and foreign pharmaceutical companies continued!
Time of Update: 2023-01-01
js?cdnversion='+~(-new Date()/36e5)];Since the beginning of this year, in order to increase the number of innovative drugs and expand the supply capacity of products and services, many domestic and foreign pharmaceutical companies are frequently launching acquisitions.
-
Sanqi price reduction, Zhongheng Group's performance is expected to recover!
Time of Update: 2023-01-01
On October 29, Guangxi Wuzhou Zhongheng Group Co. , Ltd. (Zhongheng Group, 600252) released the third quarter report of 2022, showing that the operating income in the first three quarters of 2022 was
-
Recently, many pharmaceutical companies are frequently experiencing shareholder reductions
Time of Update: 2023-01-01
Like Teyi Pharmaceutical, on November 15, BrightPharma also issued an announcement that its major shareholder Zhong Weifang plans to reduce its shares in the company through block transactions within 3 months after 3 trading days from the date of disclosure of this announcement, and the total number of shares to reduce will not exceed 2% of the company's total share capital, that is, no more than 8.
